Palmoplantar Keratoderma - Pipeline Insight, 2025
Description
DelveInsight’s, “Palmoplantar Keratoderma – Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmoplantar Keratoderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Palmoplantar Keratoderma: Overview
Palmoplantar keratoderma (PPK) is a group of skin conditions characterized by thickening of the skin on the palms of the hands and soles of the feet.PPK can be either acquired during the lifetime (more commonly) or inherited. Acquired PPKs may arise due to changes in a person's health or environment.] Inherited PPKs are caused by genetic mutations that result in abnormalities of keratin, a skin protein. Even widespread thickened skin (keratosis) over the palms and soles, A red band at the edges of the keratosis is frequent, Other keratotic lesions may appear on the tops of the hands, feet, knees, and elbows, Excessive perspiration, Nails may be thickened are common symptoms associated with PPK. Treatment options for PPK involve the use of Topical keratolytics, such as salicylic acid, Benzoic acid compounds.
""Palmoplantar Keratoderma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmoplantar Keratoderma pipeline landscape is provided which includes the disease overview and Palmoplantar Keratoderma treatment guidelines. The assessment part of the report embraces, in depth Palmoplantar Keratoderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmoplantar Keratoderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Palmoplantar Keratoderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Palmoplantar Keratoderma Emerging Drugs
Further product details are provided in the report……..
Palmoplantar Keratoderma: Therapeutic Assessment
This segment of the report provides insights about the different Palmoplantar Keratoderma drugs segregated based on following parameters that define the scope of the report, such as:
Palmoplantar Keratoderma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmoplantar Keratoderma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmoplantar Keratoderma drugs.
Palmoplantar Keratoderma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Palmoplantar Keratoderma: Overview
Palmoplantar keratoderma (PPK) is a group of skin conditions characterized by thickening of the skin on the palms of the hands and soles of the feet.PPK can be either acquired during the lifetime (more commonly) or inherited. Acquired PPKs may arise due to changes in a person's health or environment.] Inherited PPKs are caused by genetic mutations that result in abnormalities of keratin, a skin protein. Even widespread thickened skin (keratosis) over the palms and soles, A red band at the edges of the keratosis is frequent, Other keratotic lesions may appear on the tops of the hands, feet, knees, and elbows, Excessive perspiration, Nails may be thickened are common symptoms associated with PPK. Treatment options for PPK involve the use of Topical keratolytics, such as salicylic acid, Benzoic acid compounds.
""Palmoplantar Keratoderma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmoplantar Keratoderma pipeline landscape is provided which includes the disease overview and Palmoplantar Keratoderma treatment guidelines. The assessment part of the report embraces, in depth Palmoplantar Keratoderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmoplantar Keratoderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Palmoplantar Keratoderma R&D. The therapies under development are focused on novel approaches to treat/improve Palmoplantar Keratoderma.
This segment of the Palmoplantar Keratoderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Palmoplantar Keratoderma Emerging Drugs
- SGT-210: Sol-Gel technologies Ltd.
Further product details are provided in the report……..
Palmoplantar Keratoderma: Therapeutic Assessment
This segment of the report provides insights about the different Palmoplantar Keratoderma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Palmoplantar Keratoderma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Palmoplantar Keratoderma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmoplantar Keratoderma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmoplantar Keratoderma drugs.
Palmoplantar Keratoderma Report Insights
- Palmoplantar Keratoderma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Palmoplantar Keratoderma drugs?
- How many Palmoplantar Keratoderma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Palmoplantar Keratoderma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Palmoplantar Keratoderma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Palmoplantar Keratoderma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sol-Gel Technologies Ltd.
- Krystal Biotech Inc.
- SGT-201
- KB-105
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Palmoplantar Keratoderma: Overview
- ● Causes
- ● Mechanism of Action
- ● Signs and Symptoms
- ● Diagnosis
- ● Disease Management
- Pipeline Therapeutics
- ● Comparative Analysis
- Therapeutic Assessment
- ● Assessment by Product Type
- ● Assessment by Stage and Product Type
- ● Assessment by Route of Administration
- ● Assessment by Stage and Route of Administration
- ● Assessment by Molecule Type
- ● Assessment by Stage and Molecule Type
- Palmoplantar Keratoderma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- ● Palmoplantar Keratoderma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Palmoplantar Keratoderma Collaboration Deals
- ● Company-Company Collaborations (Licensing / Partnering) Analysis
- ● Company-University Collaborations (Licensing / Partnering) Analysis
- Mid Stage Products (Phase II)
- ● Comparative Analysis
- Drug Name: Company Name
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ● Comparative Analysis
- SGT-201: Sol Gel Technologies Ltd.
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- ● Comparative Analysis
- Palmoplantar Keratoderma Key Companies
- Palmoplantar Keratoderma Key Products
- Palmoplantar Keratoderma- Unmet Needs
- Palmoplantar Keratoderma- Market Drivers and Barriers
- Palmoplantar Keratoderma- Future Perspectives and Conclusion
- Palmoplantar Keratoderma Analyst Views
- Palmoplantar Keratoderma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

